Full Text View
Tabular View
Study Results
Related Studies
Aspirin Dose and Atherosclerosis in Patients With Heart Disease (TAD)
This study has been completed.
Study NCT00272337   Information provided by Florida Atlantic University

First Received on January 3, 2006.   Last Updated on June 20, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cardiovascular Diseases
Atherosclerosis
Myocardial Infarction
Additional conditions recognized in this trial
Infarction
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Heart Diseases
Ischemia
Myocardial Ischemia
Necrosis
Pathologic Processes
Vascular Diseases
Interventions listed in this trial
Aspirin
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antipyretics
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Florida Atlantic University
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services